Archer will develop and pursue regulatory approval for a companion diagnostic that will help find patients who may benefit from one of Merck's drug candidates.
The firm has completed submissions for all three of its ePlex panels for diagnosis and management of bloodstream infections that can lead to sepsis.
Cells that express genes linked to greater proliferation potential are more likely to downregulate the HIV provirus, according to a new study.
The firm's molecular assay directly detects varicella-zoster virus DNA from a patient's cerebrospinal fluid and provides results in about one hour.
The assets include significant genetic data related to women's diseases and degenerative disc disease, which Predictive will use to develop gene-based diagnostics.
The firm will use the funds to continue its commercialization plans for the Unyvero diagnostic test cartridges and instruments.
The UK-based nucleic acid sample prep solutions provider will use the funds to accelerate product development and company growth.
With RNA sequence, expression quantitative trait locus, genome-wide association, and other data, researchers identified disease-related genes in the kidney glomerulus and tubule compartments.
The collaboration will focus on the development of a bespoke silicon array to enable high-throughput production of high-fidelity gene-length DNA.
The company's shares grew 28 percent in September after it terminated a licensing deal with BioMérieux and regained control of certain intellectual property.
Over the next four years, researchers will aim to pinpoint the impact of personal genomic information given to patients with autism and their families.
The BioCode GPP tests for 17 of the most common bacteria, viruses, and parasites that cause infectious diarrhea, and runs on the BioCode MDx-3000 system.
Genetic and phenotypic data for Million Veteran Program participants led to loss-of-function changes in a gene inhibited by cilostazol.
The new genomes allowed the researchers to add 62 new coding loci to the mouse reference genome annotation and to identify a large new gene.
In granting de novo premarket authorization to ClonoSeq, the agency established its regulatory expectations for similar tests.
The placing and subscription shares that are part of the offering are expected to start trading on the AIM market of the London Stock Exchange later this month.
The company will use the proceeds in part to develop its Next Generation Profiling offering to analyze cancer genomes, transcriptomes, and proteomes with clinical outcome data.
Last week, GenomeWeb's readers were most interested in Agilent Technologies' acquisition of ACEA Biosciences for $250 million in cash.
The bipartisan bill passed both the House and Senate by large margins and increases the NIH's budget by 5.4 percent over its fiscal 2018 funding level.
The company plans to use parts of the proceeds from the offering to pay for the recent settlement with Illumina.
Researchers found that when combined into a risk score, heart disease loci identified in the general population were also associated with heart disease in type 2 diabetes.
A team led by Walter and Eliza Hall Institute researchers found that ovarian tumors with complete BRCA1 methylation and silencing were more susceptible to treatment.
The companies are developing a risk model to predict the likelihood that a prostate cancer patient will develop advanced or metastatic disease.
Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.
Wired reports that researchers have shown they could reprogram a DNA-based computer.
Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.
In Science this week: whole-genome sequencing of single sperm cells, and more.